Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Clinical Criteria for RA & Early Non-Response to Certolizumab as Predictors of Patient Outcomes

Lara C. Pullen, PhD  |  May 25, 2020

A recent study compared three clinical criteria for rheumatoid arthritis (RA) in patients using certolizumab, assessing the predictability of treatment non-response. Researchers found Clinical Disease Activity Index measurement at three months may predict patient outcomes at 12 months…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Certolizumab PegolOutcomesRheumatoid Arthritis (RA)

Driving through the Storm: A Pediatric Rheumatologist Finds a Pandemic of Rheumatic Disease

Mark Gorelik, MD  |  May 18, 2020

A pediatric rheumatologist in the thick of treating children with COVID-19 confronts a new and evolving syndrome.

Filed under:ConditionsOpinionSpeak Out Rheum Tagged with:COVID-19Pediatrics

Rheumatology Biologic Expertise Valued for COVID-19 Treatment Decisions

Catherine Kolonko  |  May 18, 2020

At the Loma Linda University Medical Center, Calif., rheumatologists play a key consulting role for COVID-19 patients who may benefit from the use of biologic treatments…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiologicscoronavirusCOVID-19cytokine storm syndromeCytokinesmacrophage activation syndrome

Fellowship Training Goes Virtual: COVID-19 Pandemic Creates Training Challenges

Catherine Kolonko  |  May 18, 2020

With telemedicine platforms and Zoom calls, technology is playing a large role in how rheumatology fellows are seeing patients and participating in lectures and conferences…

Filed under:Education & Training Tagged with:coronavirusCOVID-19EducationFellowsFellows-in-Trainingfellowshiptelemedicine

Rheum After 5: Dr. Victoria Seligman Helps Create Cambodian Healthcare

Carol Patton  |  May 15, 2020

In 2001, Victoria Seligman, MD, MPH, was vacationing in Vietnam. While traveling by train, she met a student from Yale University who was working on the school’s Cambodian Genocide Program, which documents the atrocities that occurred in Cambodia between 1975 and 1979 under the Khmer Rouge regime. Approximately 1.7 million people—representing 21% of the population—were slaughtered….

Filed under:ProfilesRheum After 5 Tagged with:Dr. Victoria SeligmanHealth Volunteers Overseas

Andrey_Popov / shutterstock.com

How Ageism Hurts Physicians & Patients

Steven M. Harris, Esq.  |  May 15, 2020

Ageism is defined as stereo­typing, prejudice or discrimination against individuals on the basis of their age. According to the American Medical Association (AMA), 43% of all physicians and surgeons are 55 or older. Specialists are, on average, older than primary care doctors. In addition, around 30% of the current U.S. population is older than 55,…

Filed under:EthicsLegal Updates Tagged with:ageism

Andrey_Popov / shutterstock.com

Rheumatology & Digital Wearables: What’s on the Horizon?

Carina Stanton  |  May 15, 2020

SNOWMASS VILLAGE, COLO.—A major workforce shortage, a population of patients taking immunosuppressants where safety concerns and the patient experience are critical, and an increasing focus on remote patient monitoring and telehealth are driving a discussion regarding the role digital wearables play in rheumatologic care. “We need to be more thoughtful and efficient in taking care…

Filed under:AppsTechnologyWorkforce Tagged with:digital wearablespatient datatelehealthWinter Rheumatology Summitworkforce shortage

Sentavio / shutterstock.com

Rheumatoid Arthritis Therapy Update: What’s Changed & What’s the Same

Kimberly Retzlaff  |  May 15, 2020

SNOWMASS VILLAGE, COLO.—Current trends in rheumatoid arthritis (RA) therapy are the increased use of newer medication categories, such as Janus kinase (JAK) inhibitors (Jakinibs) and biologics, and the rising costs of treatment. Unchanged is the consistent use of methotrexate as an effective therapy. These topics and more were discussed at the ACR Winter Symposium during…

Filed under:Biologics/DMARDsConditionsRheumatoid Arthritis Tagged with:costsjanus kinase inhibitorMethotrexateWinter Rheumatology Summit

The initial physical examination was significant for a nonblanching, papular rash along the palmar aspects of the hands and digits, periungual erythema, and edema and tenderness of the proximal and distal interphalangeal joints of the hands.

Case Report: A Patient with Clinically Amyotrophic Dermatomyositis & Associated ILD & RA Overlap

Vania Lin, MD, MPH, & Leah Krull, MD  |  May 15, 2020

Clinically amyotrophic dermatomyositis (CADM), a subset of dermatomyositis (DM), is a rare autoimmune disease characterized by typical DM cutaneous findings (e.g., heliotrope rash, Gottron papules, Gottron sign) without evidence of myositis.1 The incidence of DM and CADM is approximately 9.63 per 1 million people and 2.08 per 1 million people, respectively.2 The association with development…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Clinically Amyotrophic Dermatomyositis (CADM)combination therapyinterstitial lung disease (ILD)

Shidlovski / shutterstock.com

Studies Suggest Similar Risks for Biologics vs. Conventional Therapies for Rheumatoid Arthritis

Bryn Nelson, PhD  |  May 15, 2020

Two new studies delving into the relative safety of biologic drugs prescribed for rheumatoid arthritis (RA) have concluded that real-world applications of abatacept and tumor necrosis factor inhibitors (TNFi’s) are comparable to more conventional therapies in their associated risk of serious infections. Triple Therapy One study, in Arthritis Care & Research, found the risk of…

Filed under:ConditionsDrug UpdatesResearch RheumRheumatoid Arthritis Tagged with:abatacepttriple therapytumor necrosis factor inhibitor (TNFi)

  • « Previous Page
  • 1
  • …
  • 99
  • 100
  • 101
  • 102
  • 103
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences